Meeting
2015 ASCO Annual Meeting
FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC).
Authors
Mafalda Oliveira
Vall d'Hebron University Hospital / VHIO, Barcelona, Spain
Mafalda Oliveira , Cristina Saura , Antonio Gonzalez-Martin , Jay C. Andersen , Julie Gottlieb Fisher , Isabel Calvo , Eva Ciruelos , Miquel Gil , Lorena De La Pena , Marta Llobet-Canela , YounJeong Choi , Shidong Jia , Sreenivasu Yalamanchili , Stina Mui Singel , Premal H. Patel , Jose Baselga , Steven J. Isakoff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT02301988
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS1112)
DOI
10.1200/jco.2015.33.15_suppl.tps1112
Abstract #
TPS1112
Poster Bd #
220a
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (GDC-0068) in combination with paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer.
First Author: Steven J. Isakoff
Poster
2017 ASCO Annual Meeting
LOTUS (NCT02162719): A double-blind placebo (PBO)-controlled randomized phase II trial of first-line ipatasertib (IPAT) + paclitaxel (P) for metastatic triple-negative breast cancer (TNBC).
First Author: Rebecca Alexandra Dent
Poster
2019 ASCO Annual Meeting
Exome analysis of oncogenic pathways and tumor mutational burden (TMB) in triple-negative breast cancer (TNBC): Results of the translational biomarker program of the neoadjuvant double-blind placebo controlled GeparNuevo trial.
First Author: Sibylle Loibl
Poster
2016 ASCO Annual Meeting
LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.
First Author: Cristina Saura